Careers  |  Sign In  |  Register  |   Twitter

Sponsorship Statement

This continuing medical education activity is jointly sponsored byVindico Medical EducationBetter CME

Support Statement

This activity is supported by an educational grant from Aegerion

Target Audience

The intended audience for this activity consists of primary care physicians, general practitioners, lipidologists, cardiologists, and other health care professionals involved in the treatment of homozygous familial hypercholesterolemia (HoFH).

Program Overview

Familial hypercholesterolemia (FH) is an inherited condition, most commonly linked to a genetic mutation on chromosome 19. This genetic mutation causes high levels of low-density lipoprotein (LDL) cholesterol from birth and results in heart disease, heart attacks, and death. The severity of the condition is linked in great part to whether an individual is heterozygous or homozygous with respect to the gene mutation. HoFH, where an individual inherits an altered gene from both parents, is not as common as the heterozygous condition. However, it is a far more serious disease that can result in heart attacks and even death before the age of 30. Early identification of signs and symptoms of HoFH is important in ensuring optimal patient outcomes.

Guidelines have been established that outline appropriate treatment strategies and clinical management, from diagnosis to treatment, for HoFH patients. Knowledge of these guidelines and their implementation is useful to physicians and patients alike. Comprehension of the guidelines for both screening and treatment remains a gap in knowledge. These knowledge gaps may account for the lack of diagnosis and treatment for patients. Some figures estimate that as many as 40% of those with some form of FH remain undiagnosed and therefore untreated. Therapeutic mainstays, along with newer pharmaceutical treatment options, have the potential to change the way HoFH is treated. This activity will evaluate options and guidelines in the clinical management of HoFH.

Learning Objectives for this CME Activity

Upon completion of this activity, participants will be able to:

  • Recognize the signs and symptoms of HoFH
  • Utilize current guidelines and updates for the management of HoFH
  • Identify the pharmacotherapy available for treating HoFH, including mechanisms of action and side effects

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Vindico Medical Education and BetterCME. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This material is approved for one (1) year from the date of the original release: May 1, 2014 to April 30, 2015.

Disclosures

In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

Planning Committee and Faculty members report the following relationship(s):

Peter P. Toth, MD, PhD
Consulting Fees: Amgen, Atherotech, Kowa, LipoScience, Merck, Novartis
Speakers Bureau: Amarin, AstraZeneca, Genzyme, GlaxoSmithKline, Kowa, Merck

Raul Santos, MD, MsC, PhD
Consulting Fees: Aegerion, AstraZeneca, Amgen, Bristol-Myers Squibb, BioLab, Boehringer Ingelheim, Genzyme, Merck, Nestlé, Novo Nordisk, Novartis, Pfizer, Sanofi, Regeneron
Speakers Bureau: AstraZeneca, Aegerion, BioLab, Bristol-Myers Squibb, Merck, Novo Nordisk, Novartis, Pfizer

Reviewer reports the following relationship(s):

Ronald A. Codario, MD, FACP, CCMEP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

BetterCME staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the approved period, participants must: (1) read the learning objectives and disclosures; (2) complete the pre-test by recording the best answer to each question; (3) study the educational material; (4) complete the post-test by recording the best answer to each question; and (4) complete the evaluation form and mail the answer key and evaluation form to the address given, OR, apply for credit at the web site listed.

Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the post-test questions correctly. Upon receipt of the completed materials, if a satisfactory score on the post-test is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate. Online submissions will be processed immediately upon completion.

Submit online at http://www.thedoctorschannel.com/view/hofh-cme

Media

A hand-held slide viewer with audio narration and accompanying flash cards.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products, or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational uses of products/devices.

Copyright and Disclaimer

Created and published by BetterCME. Joint Copyright © 2014 Vindico Medical Education and BetterCME. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and BetterCME continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and BetterCME. Neither Vindico Medical Education, BetterCME, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Faculty
Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FCCP, FACC, FNLA

University of Illinois School Of Medicine

Director of Preventive Cardiology

CGH Medical Center

Sterling, Illinois

Professor of Clinical Family and Community Medicine

Peoria, Illinois

Raul Santos MD, MsC, PhD

Associate Professor of Cardiology

Director of the Lipid Clinic of the Heart Institute (InCor)

University of São Paulo

São Paulo, Brazil